Diclofenac Sodium-Misoprostol (Diclofenac Sodium/Misoprostol) Patent Expiration, LOE Window & CMS Spending

Diclofenac Sodium-Misoprostol (Diclofenac Sodium/Misoprostol) by Micro Labs USA: Off-Patent Genericized (AB Competition), 4 AB generics, $6.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMicro Labs USA
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$6.2M
2024 Medicare Part D Spend$5.9M
2024 Medicaid Spend$245K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel